On June 18th, 2024 our CEO, Jesper J. Lange, received the award as “CEO of the Year” at the annual DANISH BIO – DANSK BIOTEK Spring Gala in Copenhagen.
As a co-founder of MC2 Therapeutics, with an accomplished career in both the legal and biotech industries, Jesper J. Lange has instigated innovative cross-silo thinking within the company to exploit MC2’s in-depth knowledge of immunology and inflammation. Under his leadership the company has developed and established commercial manufacturing for its psoriasis drug and is committed to developing novel treatment paradigms with “pipeline in a product” potential such as MC2-32, to address critical gaps in treatment options for underserved diseases including Hidradenitis Suppurativa.
Jesper J. Lange has built a high-performance team, cultivating an inclusive and collaborative environment with an ambition to change the way we treat disease and transform patient outcomes on a global scale.
BACK
